
David Planchard/Oncostream.com
Mar 14, 2025, 13:20
David Planchard: Unparalleled benefit of Osimertinib for EGFR-mutated advanced NSCLC
David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, shared an article by Pasi A Jänne, et al. on X:
“Unparalleled benefit to date of osimertinib (FLAURA) and especially in combination with chemotherapy (FLAURA2) for our EGFR-mutated advanced NSCLC patients in first-line treatment with brain/meningeal metastases.”
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.
Authors: Pasi A Jänne, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 14, 2025, 13:00
Mar 14, 2025, 11:39
Mar 14, 2025, 11:15
Mar 14, 2025, 10:53
Mar 14, 2025, 09:22
Mar 14, 2025, 08:16
Mar 14, 2025, 06:56
Mar 14, 2025, 05:39
Mar 14, 2025, 05:30